Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial
Triggering global regulatory submissions this year for the treatment of obesity
Triggering global regulatory submissions this year for the treatment of obesity
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
The company is bringing precision therapies for gynaecological cancers
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Subscribe To Our Newsletter & Stay Updated